Ticino Wealth Acquires New Holdings in AbbVie Inc. $ABBV

Ticino Wealth bought a new position in AbbVie Inc. (NYSE:ABBV) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 4,099 shares of the company’s stock, valued at approximately $937,000.

A number of other hedge funds have also added to or reduced their stakes in ABBV. Chelsea Counsel Co. purchased a new position in shares of AbbVie in the 3rd quarter worth $26,000. Westend Capital Management LLC purchased a new stake in AbbVie during the fourth quarter valued at $29,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie in the third quarter valued at about $31,000. WestEnd Advisors LLC lifted its holdings in AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the period. Finally, Caitlin John LLC purchased a new position in AbbVie in the third quarter worth about $33,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Down 0.9%

NYSE:ABBV opened at $201.94 on Tuesday. The business’s 50-day simple moving average is $218.62 and its two-hundred day simple moving average is $223.14. AbbVie Inc. has a 52 week low of $170.91 and a 52 week high of $244.81. The stock has a market cap of $357.06 billion, a PE ratio of 86.12, a P/E/G ratio of 0.74 and a beta of 0.38.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 14.26 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is currently owned by insiders.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Nxera Pharma reached a third R&D milestone under its neurology collaboration with AbbVie, triggering a US$10 million payment — a sign of steady pipeline progress and potential future milestone and royalty upside. Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
• Positive Sentiment: Wall Street coverage remains constructive: RBC maintained a Buy on ABBV with a $260 target, supporting the view that analysts see upside from valuation, dividends and pipeline. AbbVie (ABBV) Is One Of The Major Stock To Buy According To Wall Street
• Positive Sentiment: Investor commentary highlights ABBV as a value/dividend buy: a 247WallStreet piece lays out reasons for buying on pullbacks (dividend reliability, buybacks/pipeline), which can attract income-focused investors on dips. Why I Can’t Stop Buying AbbVie Stock
• Positive Sentiment: Corporate/community investment: AbbVie is sponsoring a new BioLabs facility in Toronto, signaling R&D ecosystem support and potential biotech collaboration benefits over time. AbbVie Sponsors New BioLabs Facility in Toronto
• Neutral Sentiment: Marketing/brand activity: AbbVie launched a cross‑agency “PSO Done” psoriasis campaign — supports awareness and product uptake but is unlikely to move near‑term revenue guidance materially. AbbVie launches ‘PSO Done’ psoriasis campaign with a cross-agency effort
• Neutral Sentiment: Analyst blog coverage notes AbbVie alongside other large names for pipeline strength and dividend profile — helpful for sentiment but not an immediate catalyst. The Zacks Analyst Blog Microsoft, AbbVie, BHP, CBL & Associates Properties and IRIDEX
• Negative Sentiment: Oncology headwinds: Zacks warns AbbVie’s oncology unit may face declining Imbruvica sales and pricing pressure, which could weigh on Q1 top-line growth and is a near‑term earnings risk. Will AbbVie’s Oncology Franchise Weigh on Q1 Top-line Growth?
• Negative Sentiment: Market reaction: Coverage explaining today’s share drop points to investor concern about near‑term revenue pressure (oncology/pricing) and profit‑taking after recent gains, which has driven the stock lower in the latest session. Here’s Why AbbVie (ABBV) Fell More Than Broader Market

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ABBV. Citigroup lowered their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 11th. Barclays initiated coverage on AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective for the company. Canaccord Genuity Group assumed coverage on AbbVie in a research report on Monday. They set a “buy” rating and a $262.00 target price on the stock. Finally, Piper Sandler upped their price target on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $253.43.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.